Biofrontera (BFRI) Capital Expenditures (2021 - 2025)
Biofrontera's (BFRI) quarterly Capital Expenditures came in at -$1000.0 in Q4 2025, down 200.0% year-on-year from $1000.0 in Q4 2024, and little changed quarter-over-quarter from -$1000.0 in Q3 2025.
Biofrontera (BFRI) Capital Expenditures (2021 - 2025) Analysis & Trends
Biofrontera's Capital Expenditures history runs 5 years deep, the most recent figure standing at -$1000.0 for Q4 2025.
- On a quarterly basis, Capital Expenditures fell 200.0% year-over-year to -$1000.0 in Q4 2025; TTM through Dec 2025 was $2000.0, a 80.0% decrease from a year earlier, with the FY2025 full-year figure at $2000.0, down 80.0% from the prior year.
- Capital Expenditures steadied at -$1000.0 in Q4 2025 per BFRI's latest filing, from -$1000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $1.2 million in Q2 2023 and bottomed at -$48000.0 in Q2 2024.
- The 5-year median for Capital Expenditures is $1000.0 (2022), against an average of $76625.0.
- Biggest YoY gain for Capital Expenditures was 3651.61% in 2023; the steepest drop was 1000.0% in 2023.
- Year by year, Capital Expenditures stood at $9000.0 in 2021, then tumbled by 88.89% to $1000.0 in 2022, then tumbled by 1000.0% to -$9000.0 in 2023, then surged by 111.11% to $1000.0 in 2024, then sank by 200.0% to -$1000.0 in 2025.
- Per Business Quant, the three latest BFRI Capital Expenditures figures stand at -$1000.0 (Q4 2025), -$1000.0 (Q3 2025), and $1000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Biofrontera | 12.70 Mn | 6.29 Mn | 14.09 Mn | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1,000.00 |
| Dec 31, 2025 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Sep 30, 2025 | -1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Jun 30, 2024 | -48,000.00 |
| Jun 30, 2024 | -48,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Dec 31, 2023 | -9,000.00 |
| Jun 30, 2023 | 1.16 Mn |
| Jun 30, 2023 | 1.16 Mn |
| Mar 31, 2023 | 14,000.00 |
| Mar 31, 2023 | 14,000.00 |